Nature Medicine.

News

18 May 2020
Professor Tony MOK from the Faculty of Medicine of The Chinese University of Hong Kong (CU Medicine) and Professor LU You from West China School of Medicine at The Sichuan University co-led the world’s first-in-human Phase I clinical trial investigating the safety and feasibility of CRISPR gene-edit therapy as a treatment option for patients with late stage lung cancer. Research team recruited 22 advanced Non-small-cell lung carcinoma (NSCLC) patients and isolate the T cell (a form of white blood cell) from peripheral blood. After gene-editing by CRISPR, the T cells that were reinfused back to patient may have the ability to attack cancer cell. Objective of the study is to demonstrate safety and feasibility. Results demonstrated CRISPR technology is safe and feasible as patients showed no severe adverse events and the frequency of off-target events was only 0.05%. This opens a new chapter in the history of lung cancer immunotherapy. The findings were recently published on-line in the international medical journal Nature Medicine.

Events

Sorry, no events coming up for this topic.

Researchers

Sorry, no researchers coming up for this topic.